# Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

> **NCT03697551** · PHASE2 · TERMINATED · sponsor: **Ipsen** · enrollment: 4 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Satoreotide trizoxetan

## Key facts

- **NCT ID:** NCT03697551
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-22
- **Primary completion:** 2019-02-06
- **Final completion:** 2019-02-06
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Recruitment challenges and not due to safety concerns.
- **Last updated:** 2020-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03697551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03697551, "Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03697551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*